Now showing items 1-3 of 3
The Ripple Effects of a Restrictive Medicaid Formulary (editorial)
(American Journal of Managed Care, 2003-10)
Patents and New Product Development in the Pharmaceutical and Biotechnology Industry
(The Georgetown Public Policy Review, 2003-03)
The price of innovation: new estimates of drug development costs.
(J Health Econ, 2003-03)
The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of ...